<SEC-DOCUMENT>0001610618-25-000020.txt : 20250306
<SEC-HEADER>0001610618-25-000020.hdr.sgml : 20250306
<ACCEPTANCE-DATETIME>20250306165249
ACCESSION NUMBER:		0001610618-25-000020
CONFORMED SUBMISSION TYPE:	S-8
PUBLIC DOCUMENT COUNT:		5
REFERENCES 429:			333-203434
REFERENCES 429:			333-210263
REFERENCES 429:			333-216722
REFERENCES 429:			333-228282
REFERENCES 429:			333-231326
REFERENCES 429:			333-236874
REFERENCES 429:			333-253545
REFERENCES 429:			333-259219
REFERENCES 429:			333-263350
REFERENCES 429:			333-270781
REFERENCES 429:			333-278872
REFERENCES 429:			333-281523
FILED AS OF DATE:		20250306
DATE AS OF CHANGE:		20250306
EFFECTIVENESS DATE:		20250306

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cidara Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001610618
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				461537286
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-8
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-285607
		FILM NUMBER:		25716041

	BUSINESS ADDRESS:	
		STREET 1:		6310 NANCY RIDGE DRIVE
		STREET 2:		SUITE 101
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858-752-6170

	MAIL ADDRESS:	
		STREET 1:		6310 NANCY RIDGE DRIVE
		STREET 2:		SUITE 101
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	K2 THERAPEUTICS, INC.
		DATE OF NAME CHANGE:	20140611
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-8
<SEQUENCE>1
<FILENAME>cdtxs-82025x03x06.htm
<DESCRIPTION>CIDARA THERAPEUTICS, INC. FORM S-8
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i5e6089ed13eb4f72a2c9be65d7eef3ce_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As filed with the Securities and Exchange Commission on March&#160;6, 2025</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Registration No.&#160;333-</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:2pt;font-weight:400;line-height:120%">&#160;</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:115%">UNITED STATES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:115%">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Washington, D.C. 20549</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:115%">FORM S-8</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:115%">REGISTRATION STATEMENT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">UNDER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">THE SECURITIES ACT OF 1933</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:115%">CIDARA THERAPEUTICS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Exact name of registrant as specified in its charter)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:49.421%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.187%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Delaware</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">46-1537286</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(State or other jurisdiction of incorporation or organization)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(I.R.S. Employer Identification No.)</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">6310 Nancy Ridge Drive, Suite 101</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">San Diego, California</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">92121</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(Address of Principal Executive Offices)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(Zip Code)</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Cidara Therapeutics, Inc. 2015 Employee Stock Purchase Plan</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Cidara Therapeutics, Inc. 2020 Inducement Incentive Plan, as amended</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(Full titles of the plans)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Jeffrey Stein, Ph.D.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">President and Chief Executive Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cidara Therapeutics, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6310 Nancy Ridge Drive, Suite 101</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">San Diego, California 92121</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(858) 752-6170</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(Name, address, including zip code, and telephone number, including area code, of agent for service) </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Copies to&#58; </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:49.421%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.187%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Charles J. Bair, Esq.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cooley LLP</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10265 Science Center Drive</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">San Diego, California 92121</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(858) 550-6000</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Jeffrey Stein, Ph.D.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">President and Chief Executive Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cidara Therapeutics, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6310 Nancy Ridge Drive, Suite 101</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">San Diego, California 92121</font></div></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. </font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:19.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.125%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.574%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.982%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Large&#160;accelerated&#160;filer</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:100%">o</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated&#160;filer</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:100%">o</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-accelerated filer</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:100%">x</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:100%">x</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:100%">o</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. </font><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:115%">o</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">EXPLANATORY NOTE</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This Registration Statement on Form S-8 is being filed by Cidara Therapeutics, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Registrant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;) for the purpose of registering (i) an additional 24,516 shares of the Registrant&#8217;s Common Stock, par value $0.0001 per share (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;), under the Registrant&#8217;s 2015 Employee Stock Purchase Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">ESPP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;), pursuant to the provisions of the ESPP providing for an automatic increase in the number of shares of Common Stock reserved and available for issuance under the ESPP, and (ii) an additional 350,000 shares of Common Stock reserved for issuance under the Registrant&#8217;s 2020 Inducement Incentive Plan, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Inducement Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;) to employees of the Registrant as an inducement material to entry into employment with the Registrant, in accordance with Nasdaq Listing Rule 5635(c)(4), pursuant to an amendment to the Inducement Plan approved by the Compensation and Human Capital Committee of the Board of Directors of the Registrant on February 12, 2025.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">INCORPORATION BY REFERENCE OF CONTENTS OF REGISTRATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">STATEMENTS ON FORM S-8</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This Registration Statement on Form S-8 is being filed for the purpose of increasing the number of securities of the same class as other securities for which a Registration Statement on Form S-8 relating to the same benefit plans is effective. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Registrant previously registered shares of its Common Stock for issuance under the ESPP under Registration Statements on Form S-8 filed with the Securities and Exchange Commission on </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1610618/000119312515131339/d909250ds8.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">April 15, 2015</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (File No. 333-203434), </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1610618/000156459016015008/cdtx-s8_20160317.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">March 18, 2016</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (File No. 333-210263), </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1610618/000161061817000015/cdtxs-82017x03x15.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">March 15, 2017</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (File No. 333-216722), </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1610618/000161061818000111/cdtxs-82018x11x08.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">November 8, 2018</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (File No. 333-228282), </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1610618/000161061819000036/cdtxs-82019x05x09.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">May 9, 2019</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (File No. 333-231326), </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1610618/000161061820000012/cdtxs-82020x03x03.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">March 4, 2020</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (File No. 333-236874), </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1610618/000161061821000012/cdtxs-82021x02x25.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">February 25, 2021</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (File No. 333-253545), </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1610618/000161061822000011/cdtxs-82022x03x07.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">March 7, 2022</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (File No. 333-263350), </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1610618/000161061823000024/cdtxs-82023x03x23.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">March 23, 2023</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (File No. 333-270781) and </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1610618/000161061824000046/cdtxs-82024x04x22.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">April 23, 2024</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (File No. 333-278872). </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Registrant previously registered shares of its Common Stock for issuance under the Inducement Plan under Registration Statements on Form S-8 filed with the Securities and Exchange Commission on </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1610618/000161061821000012/cdtxs-82021x02x25.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">February 25, 2021</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (File No. 333-253545), </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1610618/000161061821000074/cdtxs-82021x08x31.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">August 31, 2021</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (File No. 333-259219) and </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1610618/000161061824000119/cdtxs-82024x08x13.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">August 13, 2024</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (File No. 333-281523).</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to General Instruction E to Form S-8, this Registration Statement hereby incorporates by reference the contents of the Registration Statements referenced above.</font></div><div><font><br></font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">ITEM 8.            EXHIBITS.</font></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Exhibit Number</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Description</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1610618/000119312515146688/d914065dex31.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K, filed on April 24, 2015).</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1610618/000161061824000041/exhibit322023-12.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.2 of the Registrant&#8217;s Annual Report on Form 10-K, filed with the SEC on April 22, 2024).</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1610618/000161061824000091/exhibit312024-07x18.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Certificate of Amendment to Amended and Restated Certificate of Incorporation of Cidara Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K, filed on July 18, 2024).</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.4</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1610618/000119312515146688/d914065dex32.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Amended and Restated Bylaws of the Registrant, as currently in effect (incorporated by reference to Exhibit 3.2 to the Registrant&#8217;s Current Report on Form 8-K, filed on April 24, 2015).</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.5</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1610618/000161061818000052/ex312018-05x21.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Certificate of Designation of Preferences, Rights and Limitations of Series X Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K, filed on May 21, 2018).</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1610618/000161061824000051/exhibit312024-04x24.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Voting Preferred Stock (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K, filed on April 24, 2024).</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1610618/000119312515119340/d843130dex41.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Form of Common Stock Certificate of the Registrant (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-202740), as amended, originally filed on March 13, 2015).</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.1*</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="exhibit512025-03x06.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Opinion of Cooley LLP.</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">23.1*</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="exhibit2312025-03x06.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Consent of Independent Registered Public Accounting Firm.</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">23.2*</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="exhibit512025-03x06.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Consent of Cooley LLP. Reference is made to Exhibit 5.1.</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">24.1*</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#i5e6089ed13eb4f72a2c9be65d7eef3ce_4" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Power of Attorney. Reference is made to the signature page hereto.</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">99.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1610618/000119312515091277/d843130dex103.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">2015 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.3 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-202740), as amended, originally filed on March 13, 2015).</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">99.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1610618/000161061825000017/exhibit1072024-12.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">2020 Inducement Incentive Plan, as amended (incorporated by reference to Exhibit 10.7 of the Registrant&#8217;s Annual Report on Form 10-K, filed with the SEC on March 6, 2025).</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">107*</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a href="exhibit1072025-03x06.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Filing Fee Table.</a></font></div></td></tr></table></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">* Filed herewith.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i5e6089ed13eb4f72a2c9be65d7eef3ce_4"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:1.1pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SIGNATURES</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on March&#160;6, 2025. </font></div><div style="margin-top:6pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.860%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">CIDARA THERAPEUTICS, INC.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Jeffrey Stein, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Jeffrey Stein, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">President and Chief Executive Officer</font></td></tr></table></div><div style="margin-top:1pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">POWER OF ATTORNEY </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">KNOW ALL BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Jeffrey Stein, Ph.D. and Frank Karbe and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or either of them, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated. </font></div><div style="margin-top:6pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"><tr><td style="width:1.0%"></td><td style="width:37.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.878%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.810%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.878%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Signature</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Title</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Date</font></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#47;s&#47; Jeffrey Stein, Ph.D.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">President, Chief Executive Officer and</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Member of the Board of Directors</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(Principal Executive Officer)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 6, 2025</font></td></tr><tr style="height:23pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Jeffrey Stein, Ph.D.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#47;s&#47; Frank Karbe</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chief Financial Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(Principal Financial Officer and</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Principal Accounting Officer)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 6, 2025</font></td></tr><tr style="height:23pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Frank Karbe</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#47;s&#47; Daniel D. Burgess</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chairman of the Board of Directors</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 6, 2025</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Daniel D. Burgess</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#47;s&#47; Bonnie Bassler, Ph.D.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Member of the Board of Directors</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 6, 2025</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Bonnie Bassler, Ph.D.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#47;s&#47; Carin Canale-Theakston</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Member of the Board of Directors</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 6, 2025</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Carin Canale-Theakston</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#47;s&#47; James Merson, Ph.D.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Member of the Board of Directors</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 6, 2025</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">James Merson, Ph.D.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#47;s&#47; Chrysa Mineo</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Member of the Board of Directors</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 6, 2025</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Chrysa Mineo</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#47;s&#47; Josh Resnick, M.D.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Member of the Board of Directors</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 6, 2025</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Josh Resnick, M.D.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#47;s&#47; Theodore R. Schroeder</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Member of the Board of Directors</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 6, 2025</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Theodore R. Schroeder</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#47;s&#47; Ryan Spencer</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Member of the Board of Directors</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 6, 2025</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Ryan Spencer</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>2
<FILENAME>exhibit1072025-03x06.htm
<DESCRIPTION>CALCULATION OF FILING FEE TABLES
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ib9998f5f7ffa4bd6b53d276f37327078_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 107</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Calculation of Filing Fee Tables</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form S-8</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Form Type)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cidara Therapeutics, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Exact Name of Registrant as Specified in its Charter)</font></div><div style="text-align:center"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.159%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.159%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.159%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.159%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.159%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.162%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="24" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%">Table 1 &#8211; Newly Registered Securities</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%">Security Type</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%">Security Class Title</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%">Fee Calculation Rule</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount Registered</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%">Proposed Maximum Offering Price Per Unit</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%">Maximum Aggregate Offering Price</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%">Fee Rate</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%">Amount of Registration Fee</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">Fees to be Paid</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">Equity</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.75pt;padding-left:12.75pt;padding-right:2.75pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:139%">Cidara Therapeutics, Inc. 2015 Employee Stock Purchase Plan </font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common Stock, $0.0001 par value per share</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">Other</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:133%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:1.37pt;padding-right:1.37pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;24,516</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;$19.530</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">$478,798</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">0.0001531</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">$74</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">Fees to be Paid</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">Equity</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.75pt;padding-left:12.75pt;padding-right:2.75pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:139%">Cidara Therapeutics, Inc. 2020 Inducement Incentive Plan, as amended </font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common Stock, $0.0001 par value per share</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">Other</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:133%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;350,000</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;$22.977</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">$8,041,950</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">0.0001531</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">$1,232</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="12" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">Total Offering Amounts</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">$8,520,748</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">$1,306</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="12" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">Total Fee Offsets</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">&#8211;</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="12" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">Net Fee Due</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">$1,306</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(1)&#160;&#160;&#160;&#160;Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), this Registration Statement shall also cover any additional shares of common stock, par value $0.0001 per share (&#8220;Common Stock&#8221;), of Cidara Therapeutics, Inc. (the &#8220;Registrant&#8221;) that become issuable under the Cidara Therapeutics, Inc. 2015 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;) and the Cidara Therapeutics, Inc. 2020 Inducement Incentive Plan, as amended (the &#8220;Inducement Plan&#8221;) by reason of any stock dividend, stock split, recapitalization or any other similar transaction effected without receipt of consideration which results in an increase in the number of outstanding shares of Common Stock.</font></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(2)&#160;&#160;&#160;&#160;Represents shares of Common Stock that were automatically added to the shares authorized for issuance under the ESPP on January 1, 2025 pursuant to an &#8220;evergreen&#8221; provision contained in the ESPP. Pursuant to such provision, on January 1 of each calendar year through 2025, the number of shares authorized for issuance under the ESPP is automatically increased by a number equal to the lesser of&#58; (a) 1% of the total number of shares of capital stock outstanding on December 31 of the preceding calendar year&#59; (b) 24,516 shares&#59; or (c) a lesser number of shares of Common Stock as is determined by the Registrant&#8217;s board of directors (the &#8220;Board&#8221;) that is less than (a) and (b).</font></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(3)&#160;&#160;&#160;&#160;This estimate is made pursuant to Rule 457(h)(1) and Rule 457(c) of the Securities Act solely for purposes of calculating the registration fee. The price per share and aggregate offering price are based upon the average of the high and low prices of the Common Stock on February&#160;27, 2025, as reported on the Nasdaq Capital Market, multiplied by 85%, which is the percentage of the price per share applicable to purchases under the ESPP.</font></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(4)&#160;&#160;&#160;&#160;Represents an increase in the number of shares of Common Stock reserved for issuance under the Inducement Plan pursuant to an amendment to the Inducement Plan approved by the Compensation and Human Capital Committee of the Board on February 12, 2025.</font></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(5)&#160;&#160;&#160;&#160;This estimate is made pursuant to Rule 457(h)(1) and Rule 457(c) of the Securities Act solely for purposes of calculating the registration fee. The price per share and aggregate offering price are based upon the average of the high and low prices of the Common Stock on February&#160;27, 2025, as reported on the Nasdaq Capital Market.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>exhibit512025-03x06.htm
<DESCRIPTION>CONSENT OF COOLEY LLP
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i038c80883a614e31b1255fd8407b1b5c_1"></div><div style="min-height:126pt;width:100%"><div><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><img alt="cooleylogo.jpg" src="cooleylogo.jpg" style="height:44px;margin-bottom:5pt;vertical-align:text-bottom;width:134px"></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 5.1</font></td></tr></table></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Charles J. Bair</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+1 858 550 6142</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cbair&#64;cooley.com</font></div></div><div style="margin-bottom:12pt;margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;6, 2025 </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cidara Therapeutics, Inc.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6310 Nancy Ridge Drive, Suite 101</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Diego, California 92121</font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Re&#58; Registration Statement on Form S-8</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ladies and Gentlemen&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have acted as counsel to Cidara Therapeutics, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), in connection with the filing by the Company of a Registration Statement on Form S-8 (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Registration Statement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) with the Securities and Exchange Commission (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commission</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) covering the offering by the Company of up to 374,516 shares (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shares</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) of its common stock, $0.0001 par value per share (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), consisting of (a) 350,000 shares of Common Stock issuable pursuant to the Company&#8217;s 2020 Inducement Incentive Plan, as amended (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inducement Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), and (b) 24,516 shares of Common Stock issuable pursuant to the Company&#8217;s 2015 Employee Stock Purchase Plan (together with the Inducement Plan, the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Plans</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with this opinion, we have examined and relied upon (a) the Registration Statement and the related prospectuses, (b) the Plans, (c) the Company&#8217;s certificate of incorporation, and bylaws, each as currently in effect, and (d) such other records, documents, opinions, certificates, memoranda and instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below. We have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to originals of all documents submitted to us as copies, the accuracy, completeness and authenticity of certificates of public officials, and the due authorization, execution and delivery of all documents by all persons other than the Company where authorization, execution and delivery are prerequisites to the effectiveness thereof. As to certain factual matters, we have relied upon a certificate of an officer of the Company and have not independently verified such matters.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our opinion is expressed only with respect to the General Corporation Law of the State of Delaware. We express no opinion to the extent that any other laws are applicable to the subject matter hereof and express no opinion and provide no assurance as to compliance with any federal or state securities law, rule or regulation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Shares, when sold and issued in accordance with the Plans, the Registration Statement and the related prospectuses, will be validly issued, fully paid and nonassessable (except as to shares issued pursuant to deferred payment arrangements, which will be fully paid and nonassessable when such deferred payments are made in full).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Cooley LLP   10265 Science Center Drive   San Diego, CA   92121</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> t&#58; (858) 550-6000  f&#58; (858) 550-6420  cooley.com</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:126pt;width:100%"><div><font><br></font></div><div><img alt="cooleylogo.jpg" src="cooleylogo.jpg" style="height:41px;margin-bottom:5pt;vertical-align:text-bottom;width:128px"></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;6, 2025</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page Two</font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This opinion is limited to the matters expressly set forth in this letter, and no opinion has been or should be implied, or may be inferred, beyond the matters expressly stated. This opinion speaks only as to law and facts in effect or existing as of the date hereof, and we have no obligation or responsibility to update or supplement this opinion to reflect any facts or circumstances that may hereafter come to our attention or any changes in law that may hereafter occur.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consent to the filing of this opinion as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act of 1933, as amended, or the rules and regulations of the Commission thereunder.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sincerely,</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cooley LLP</font></div><div style="margin-top:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;   </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Charles J. Bair</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Charles J. Bair</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Cooley LLP   10265 Science Center Drive   San Diego, CA   92121</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> t&#58; (858) 550-6000  f&#58; (858) 550-6420  cooley.com</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>exhibit2312025-03x06.htm
<DESCRIPTION>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i6372e638b56f4a1a9fe2754f5effcb54_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;23.1</font></div></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Consent of Independent Registered Public Accounting Firm</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the 2015 Employee Stock Purchase Plan and 2020 Inducement Incentive Plan, as amended, of Cidara Therapeutics, Inc. of our report dated March&#160;6, 2025, with respect to the consolidated financial statements of Cidara Therapeutics, Inc. included in its Annual Report (Form 10-K) for the year ended December&#160;31, 2024, filed with the Securities and Exchange Commission.</font></div><div style="margin-top:12pt"><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#47;s&#47; Ernst &#38; Young LLP</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">San Diego, California</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">March&#160;6, 2025</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>cooleylogo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cooleylogo.jpg
M_]C_X  02D9)1@ ! 0( =@!V  #_VP!#  4#! 0$ P4$! 0%!04&!PP(!P<'
M!P\+"PD,$0\2$A$/$1$3%AP7$Q0:%1$1&"$8&AT='Q\?$Q<B)"(>)!P>'Q[_
MVP!# 04%!0<&!PX(" X>%!$4'AX>'AX>'AX>'AX>'AX>'AX>'AX>'AX>'AX>
M'AX>'AX>'AX>'AX>'AX>'AX>'AX>'A[_P  1" &(!+ # 2(  A$! Q$!_\0
M&P ! 0$! 0$! 0            @'!@4$ PG_Q !*$  " 0,$  ,#"00&" 0'
M 0   0(#!!$%!A(A!Q,Q"")!%!46(S(W476S5H&5TB1A<82QM!@E,T)259/3
M%S0U4T-&97)SI,-B_\0 ' $!  $% 0$               4" P0&!P@!_\0
M0Q$  @$" @4(!@D#! ,  P    $" P0%$08A,4%1$A,B87&!D:$',G*QP=$4
M%3,T-4)24_ CLN$78H+")$.2HM+Q_]H # ,!  (1 Q$ /P"RP
M
M
M   "'O$K[QMS?F]W^M(N$A[Q*^\;<WYO=_K2([$?5B=%]'7WFM[*]YSX (HZ
MR   5#[)?W<ZA^;U/T:)L!C_ +)?W<ZA^;U/T:)L!/VWV43S_I/^+5_:  +Y
M @
M                                 X?>/BMLG:]6M:W>J_*[ZCU*TLH>
M;-/EQ<7+J$9)IYC*2:QZ=K-,IQ@LY/(R;6SKW<^;H0<GU+,[@$W;K]H?5KGS
M*&VM'M["F_,@KBZEYU5I]0G&*Q&$EVVGS6<>J7>=ZMXE;]U2YC<7.Z]4ISC!
M02M:SMXXRWW&EQ3??KC/I^",2=_3CLUFW6>@6)5URJKC#M>;\LUYEFZC?66F
MV=2]U&\M[.UIXYUJ]54X1RTEF3:2RVE^\\?Z<;*_:_;_ /$J/\Q#P,=XB]T2
M>I^CFBETZ[;ZHI?%EJZMXE;"TNVC<7.Z]+J0E-02M:RN)9PWW&ER:77KC'I^
M*/+_ /&?PU_:3_\ 1N/^V1\"EXA4W)&73]'F'I=.I-OJY*^#+!_\9_#7]I/_
M -&X_P"V=!].-E?M?M_^)4?YB'@%B$]Z134]'=B\N;JR7;D_@BX?IQLK]K]O
M_P 2H_S'0'\_CZ-.OKW3;RG>Z=>7%G=4\\*U"JZ<XY33Q)--93:_>5QQ%[XF
M)6]',&OZ5=I]<<_<UEYE\@C;;_BSO_1N$*6X;B[HJLJLZ=\E<<_3,7.>9J+2
MQB,EZMK#>33-K^T70=.-/<^@5(S4).5?3IJ2E+ETO+FUQ7'U?-]KT[ZR(7U*
M6W4:]>Z#8I;K.FE474]?@\O+,WT'/[2WKM;=?F+0-9M[RI3RYTL2IU4EC,N$
MTI<?>2Y8QEXSDZ RU)26:9J5:A5H3<*L7%K<UD_!@ 'TM
M
M                   A[Q*^\;<WYO=_K2+A(>\2OO&W-^;W?ZTB.Q'U8G1?
M1U]YK>RO><^ "*.L@  %0^R7]W.H?F]3]&B; 8_[)?W<ZA^;U/T:)L!/VWV4
M3S_I/^+5_:  +Y @
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MGUC&99RY*3H7RET9ZF<OQW0:I;1E7L6Y17Y7ZR[./O[2A0 2!ST
M
M                     $/>)7WC;F_-[O\ 6D7"0]XE?>-N;\WN_P!:1'8C
MZL3HOHZ^\UO97O.? !%'60  "H?9+^[G4/S>I^C1-@,?]DO[N=0_-ZGZ-$V
MG[;[*)Y_TG_%J_M  %\@0
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MZ8VDL2N$OUS_ +F  72,
M                                               !#WB5]XVYOS>[
M_6D7"0]XE?>-N;\WN_UI$=B/JQ.B^CK[S6]E>\Y\ $4=9   *A]DO[N=0_-Z
MGZ-$V Q_V2_NYU#\WJ?HT38"?MOLHGG_ $G_ !:O[0 !?($
M
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M0^SCV(\ZXW^)7'MS_N8 !=(L
M                                                   $/>)7WC;F
M_-[O]:1<)#WB5]XVYOS>[_6D1V(^K$Z+Z.OO-;V5[SGP 11UD   J'V2_NYU
M#\WJ?HT38#'_ &2_NYU#\WJ?HT38"?MOLHGG_2?\6K^T  7R!
M
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M&_Q*X]N?]S  +I%@
M                                           A[Q*^\;<WYO=_K2+A
M(>\2OO&W-^;W?ZTB.Q'U8G1?1U]YK>RO><^ "*.L@  %0^R7]W.H?F]3]&B;
M 8_[)?W<ZA^;U/T:)L!/VWV43S_I/^+5_:  +Y @
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M4Y_9GF4L)=2>&^*,VE=TZFI/)FDXIHGB6')SE#E16^.OQ6U>&1H  ,DUH
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M7.2Z6>4N4LM9><OMGL&Q48<B"B><\8O'>WU6OGGRI/+LV+RR  +A&@
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MSFD8E_55&UJU&\LHMY\,DRT0 ;(>;
M      8_[4&\/F?:M/;=E7XWVK9\[A/$J=M%^]G$DUS>(]IJ4541KES7H6MM
M5N;FM3H4*4'.I4J248PBEER;?227>2)O$O=-?>.\[_6ZCJ*A4GPM*<\_54(]
M0CC+2>/>:3QRE)KU,.]J\BGDMK-RT*PCZ=?\]-="GK[]R^/<<V "%.V
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MU)9*>J7M<>]>:SVLZ0 $@<\   !#WB5]XVYOS>[_ %I%PD/>)7WC;F_-[O\
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M#7[QML_F]I^M$KI/*:?68.*4U5LJU-[XR7BF7" #8SS>
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M9-^3+J+;[DX8RE]9E_9*Q)ZUJ\[33>TX)I3A'U9B$H170ETH]CW=SU=F7$
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M?)J-O>3^3TN?/C1D^5+O+;]R47V\_CWDY\UJ2<6TSTS0K1KTHU8;))-=CU@
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MK3[N=/\ S>G^C6)>(:_>=7+J.SZ T8PPQS6V4GY9+^=H !A&[@
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M2SQDI1SCO&5TR6L*N<7![CD>G^%NE<QO8^K/4_:2U>*]S/8 !('/0
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MVT,26"T?^7]T@ #&-H                              /Z @ V8\P@
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M&P0FIQ4EL//EY:5;*O*A664HO)_S@]JZ@ "HQ@
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M/\IT '(CP'TZY_<EXLY_Z#[*_9#;_P##:/\ */H/LK]D-O\ \-H_RG0 <B/
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M6WA+DXOM)O')1<C2":A.,URHLXE?6-Q8UG1N(\F2_F:XH  K,0
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MLT%GI*7<EZ>]R7;FL4:;!0JJK!2//6.X3/"[R5"2Z.V+XK=\GU@ %XAP
M        2%[0&\:&[M\25A.I+3M-@[2B_.4Z=62F^=:"724NDFF\QA%O\%MO
MM#[Z^BVU7I>F7WDZWJ.(T_*J8JT*.7SJ^CQG'!/*>9-Q>8,DXB[^M_ZUWG4=
M L%<4\0JKJC\7\%W@ $:=-   /LT/3J^KZU8Z3;2IPKWMS3MZ<JC:BI3DHIM
MI-XR_P &7;IEE;:;IMMIUE2\JUM:,*-&')RXPBE&*R\MX27;)B]E?09ZCO\
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MLS[VAH&YY[>U"M45AJ\X0H84I*G=948=)XBII\6\-Y4,X2;*E)ZVJ\Y33WG
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M]XE?>-N;\WN_UI$=B/JQ.B^CK[S6]E>\Y\ $4=9   *A]DO[N=0_-ZGZ-$V
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M$^XQ?]4I=X4<K (:I4E4ERI':</P^AA]"-"A'**\6^+ZS0/##Q6W!LGA9?\
MJ6C1YOY!5FH\)2[S">&X]K..XO,NLODJ9V#OW;>];/SM'N^-Q'DZEE7<8W%-
M1:7)P3>8^]'WDVN\9SE*)CZ-.OKW3;RG>Z=>7%G=4\\*U"JZ<XY33Q)--93:
M_>7Z%W.EJ>M$!CFB-IB>=6'0J<5L?:OCM[2^08-X7>/'RV\MM'WG2M[>53%.
M.J4WPARQ%+S8>D<ODW--165[L5EK=;:O0NK:E<VU:G7H58*=.I3DI1G%K*DF
MNFFN\DO2K0JK.+.08I@]WA=7F[F.7![4^Q_QGZ  ND8         ?G<T*%U;
M5;:YHTZ]"K!PJ4ZD5*,XM8<6GTTUU@B;Q+VM7V=O._T2HJCH4Y\[2I//UM"7
M<)9PDWCW6TL<HR2]"W3'_:@V?\\;5I[DLJ'*^TG/G<(9E4MI/WLXBV^#Q+MI
M1BZC,.]I<NGFMJ-RT*Q?Z#?\S-]"IJ[]S^'>2\ "%.V        [#P=VG],=
M^66EUH<K&E_2;[O'U,&LQ^TG[S<89B\KEGX'V,7*2BBQ=7-.UHRKU7E&*;?<
M43[.FVJ>@^&]I=U+?R[[5OZ77D^+;@_]DDX]\>&))-O#G+TSA:0 ;%3@H145
MN/.=_>3O;F=Q/;)M]G5W;  "LQ            #Q]X[:TG=F@UM&UFW\VWJ>
M]&4>ITIKTG!_"2R_[<M---IR%XC[!UW9&JU+>_MZE>P<TK?4(4VJ-9/+BL^D
M9XB\P;RL/&5ANU3X]:TO3]:TJXTK5;6G=V5S#A5I374E_BFGAIKM-)K#1C7%
MM&LL]YLVCNDU?!Y\E]*F]JX=:Z_)^9!0.\\8/#?4-AZJIP=2[T6YFU:7;7:?
MKY=3'2FEGOTDEE8Q)1X,A)P<'R9;3M]G>4;VC&O0EG%_SQ  *3)
M/0T?7-:T;S?F?6-0T[SL>;\EN9TN>,XY<6LXR\9_%GH?3C>O[7[@_B5;^8Y\
M'U2DMC+$[6A4ERIP3?6D=!].-Z_M?N#^)5OYCGP Y-[654Z%*EGS<4L^"R
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M&4))X<6GVFGU@AZM&=)Y21V+#,8M,4I\Y;3SXK>NU?Q<#\P 6R3
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MDO1(]0F+:U5+6];.-:1Z4UL7ES5/.-);M[ZW\MBZP #+-3
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M1RGW)9:Y,T  SH0C!9161HUW>W%Y4YRXFY/K_FKN  *C%
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M*EPFN+S3A]F&)1RGW)9:Y,T  SH0C!9161HUW>W%Y4YRXFY/K_FKN  *C%
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MSO.D !-'%
M
M
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MHPS%X?'/Q.P)ZUI<U32>TX%I1BJQ/$9U(/H1Z,>Q;^]YOL  ,@UX
M
M
M
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M@
M
M
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M:8
M
M
M                              #B_&O<T-K>'6I7D:E2%W=0=G9NG.4)
M*K4BTI*23XN,5*?P^QC*;13.2A%R>XR+2VG=5X4*:UR:2[R<O'K>'TMWY<?)
M:_F:9IV;6SXSS">'[]18DXOE+TDL9C&&?0S\ UV<W.3D]YZ,LK2G9V\+>GLB
MLOYV[0 "DR@>IM+1J^X=SZ;H=OYD9WMS"BYPI.HZ<6_>GQ7JHQS)]KI/M'EE
M >REL_\ \WO2^H?C:Z?SA_U*BS'^R"E%_P#N)EVA2YV:B1..XG'#+&=P]J62
M[7L^?8C>=,LK;3=-MM.LJ7E6MK1A1HPY.7&$4HQ67EO"2[9] !L)YXE)R;;>
ML  'P
M
M
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M@^C3V^T_DO-M  &>:"
M
M
M                                                3][5N\/_ "FR
M[&O^%UJ'"?\ TZ;Q+^V;C)?^VT3^ 0%U)RJO,[]HM;4[?"J*@O67*?:];_G
M  L&P _2VH5[JYI6UM1J5Z]6:A3ITXN4IR;PHI+MMOK  2S914DXP<EN1<NR
MM MMK[5T[0+27.G9T5!SPUYDVW*<\-O'*3E+&>LX72/8 -E2262/-%6K.M.5
;2;S;>;?%O:  ?2V                  ?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
